The Mechanisms of Action and the Role of Alpha Interferon in the Therapy of Myeloma

[1]  J. Wasserman,et al.  Influence of interferon on antibody production and viability of malignant cells from patients with multiple myeloma , 1991, European journal of haematology.

[2]  M. Björkholm,et al.  Natural killer cell activity in monoclonal gammopathies: Relation to disease activity , 1990, European journal of haematology.

[3]  F. Mandelli,et al.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.

[4]  J. Peter,et al.  B‐cell surface phenotypes of proliferating myeloma cells: Target antigens for immunotherapy , 1990, American journal of hematology.

[5]  S. Eksborg,et al.  Oral melphalan pharmacokinetics: Influence of interferon‐induced fever , 1990, Clinical pharmacology and therapeutics.

[6]  H. Strander,et al.  Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCS , 1989, European journal of haematology.

[7]  M. Boccadoro,et al.  The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. , 1989, Blood.

[8]  W. Scheithauer,et al.  VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma. , 1989, Onkologie.

[9]  D. Grandér,et al.  Interferon exerts a cytotoxic effect on primary human myeloma cells. , 1988, European journal of cancer & clinical oncology.

[10]  G. Gahrton,et al.  High doses of natural α‐interferon (α‐IFN) in the treatment of multiple myeloma — A pilot study from the Myeloma Group of Central Sweden (MGCS) , 1988 .

[11]  H. Asaoku,et al.  Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. , 1988, Blood.

[12]  T. Tötterman,et al.  Effects of recombinant interferon-alpha and -gamma on B-CLL cells in serum-free medium: expression of activation, differentiation, and CALLA antigens. , 1987, Leukemia.

[13]  E. Bonnem,et al.  Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase. , 1986, Cancer treatment reports.

[14]  M. Ratain,et al.  The role of interferon in the treatment of hairy cell leukemia. , 1986, Seminars in oncology.

[15]  J. Sporn,et al.  Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. , 1986, Seminars in oncology.

[16]  W. Scheithauer,et al.  Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. , 1986, European journal of cancer & clinical oncology.

[17]  A. Gazdar,et al.  Establishment and Characterization of a Human Plasma Cell Myeloma Culture Having a Rearranged Cellular myc Proto-oncogene , 1986 .

[18]  K. Kimura,et al.  Treatment of multiple myeloma with recombinant interferon alfa‐2a , 1986, Cancer.

[19]  H. Ozer,et al.  B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. , 1986, Blood.

[20]  F. Cavalli,et al.  Prednimustine: the rationale for clinical development. , 1986, Seminars in oncology.

[21]  Friedman Rm.  Growth factors, oncogenes, and interferons. , 1986 .

[22]  H. Strander.  Interferon treatment of human neoplasia. , 1986, Advances in cancer research.

[23]  M. Clemens.  Cell proliferation: Interferons and oncogenes , 1985, Nature.

[24]  B. Johansson,et al.  Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. , 1984, Cancer treatment reports.

[25]  P. Weck,et al.  Comparative Biologic Activities of Human Interferons , 1984 .

[26]  S. Grossberg,et al.  The Cellular Effects of Interferon , 1984 .

[27]  M. Björkholm,et al.  Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications. , 1984, Advances in cancer research.

[28]  W. Carter,et al.  Interferons and Their Applications , 1984, Handbook of Experimental Pharmacology.

[29]  J. Gutterman,et al.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. , 1983, Blood.

[30]  H. Strander,et al.  Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon‐induced enhancement of natural killer activity and clinical response to human interferon‐α , 1982, International journal of cancer.

[31]  H. Schreiber,et al.  Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes. , 1980, Journal of immunology.

[32]  H. Strander,et al.  Interferon therapy for neoplastic diseases in man in vitro and in vivo studies. , 1978, Advances in experimental medicine and biology.

[33]  D. Killander,et al.  Bone marrow kinetic studies on three patients with myelomatosis. Indications for malignant proliferation within both the plasma cell and lymphoid cell compartments. , 2009, Acta medica Scandinavica.

[34]  I. Gresser,et al.  Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Cantell,et al.  Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon. , 1975, The Journal of general virology.

[36]  I. Gresser,et al.  Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.